NYSE American - Delayed Quote USD

Protalix BioTherapeutics, Inc. (PLX)

1.1300 -0.0200 (-1.74%)
At close: April 18 at 4:00 PM EDT
1.1300 0.00 (0.00%)
After hours: April 18 at 6:08 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Dror Bashan President, CEO & Director 473.16k -- 1967
Mr. Eyal Rubin M.B.A. Senior VP, CFO, Treasurer & Corporate Secretary 813.73k -- 1976
Mr. Yaron Naos Senior Vice President of Operations 409.95k -- 1964
Ms. Yael Fellous Vice President of Human Resources -- -- --

Protalix BioTherapeutics, Inc.

Science Park
2 Snunit St. POB 455
Karmiel, 2161401
Israel
972 4 902 8100 https://www.protalix.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
208

Description

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

Corporate Governance

Protalix BioTherapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 5. The pillar scores are Audit: 3; Board: 8; Shareholder Rights: 1; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 02, 2024 - May 06, 2024
Protalix BioTherapeutics, Inc. Earnings Call

Related Tickers

BLRX BioLineRx Ltd.
0.6401
+2.88%
 
RVPH Reviva Pharmaceuticals Holdings, Inc.
3.0200
-5.63%
 
ENLV Enlivex Therapeutics Ltd.
1.4000
-5.41%
 
CANF Can-Fite BioPharma Ltd.
1.9700
+0.51%
 
PIRS Pieris Pharmaceuticals, Inc.
0.1552
-1.21%
 
CDTX Cidara Therapeutics, Inc.
0.7220
-0.03%
 
MCRB Seres Therapeutics, Inc.
0.5842
-6.87%
 
OCUP Ocuphire Pharma, Inc.
1.6700
-4.02%
 
XTLB XTL Biopharmaceuticals Ltd.
2.4400
-1.21%
 
PLUR Pluri Inc.
5.05
-2.32%